- Home
- SDHI vs ANNX Comparison
SDHI vs ANNX Comparison
Compare SDHI & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHI
- ANNX
- Stock Information
- Founded
- SDHI 2024
- ANNX 2011
- Country
- SDHI United States
- ANNX United States
- Employees
- SDHI N/A
- ANNX N/A
- Industry
- SDHI Blank Checks
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- SDHI Finance
- ANNX Health Care
- Exchange
- SDHI Nasdaq
- ANNX Nasdaq
- Market Cap
- SDHI 358.1M
- ANNX 334.1M
- IPO Year
- SDHI 2025
- ANNX 2020
- Fundamental
- Price
- SDHI $10.28
- ANNX $3.04
- Analyst Decision
- SDHI
- ANNX Strong Buy
- Analyst Count
- SDHI 0
- ANNX 4
- Target Price
- SDHI N/A
- ANNX $13.00
- AVG Volume (30 Days)
- SDHI 110.2K
- ANNX 2.1M
- Earning Date
- SDHI 01-01-0001
- ANNX 11-10-2025
- Dividend Yield
- SDHI N/A
- ANNX N/A
- EPS Growth
- SDHI N/A
- ANNX N/A
- EPS
- SDHI N/A
- ANNX N/A
- Revenue
- SDHI N/A
- ANNX N/A
- Revenue This Year
- SDHI N/A
- ANNX N/A
- Revenue Next Year
- SDHI N/A
- ANNX N/A
- P/E Ratio
- SDHI N/A
- ANNX N/A
- Revenue Growth
- SDHI N/A
- ANNX N/A
- 52 Week Low
- SDHI $10.00
- ANNX $1.29
- 52 Week High
- SDHI $10.45
- ANNX $6.22
- Technical
- Relative Strength Index (RSI)
- SDHI N/A
- ANNX 51.22
- Support Level
- SDHI N/A
- ANNX $2.54
- Resistance Level
- SDHI N/A
- ANNX $3.03
- Average True Range (ATR)
- SDHI 0.00
- ANNX 0.25
- MACD
- SDHI 0.00
- ANNX -0.04
- Stochastic Oscillator
- SDHI 0.00
- ANNX 50.00
About SDHI Siddhi Acquisition Corp Class A Common stock
Siddhi Acquisition Corp is a blank check company.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.